UCLA Campus    |   UCLA Health    |   School of Medicine Translate:
UCLA Health It Begins With U

Non-AIDS Defining Cancer

HIV infection, while highly treatable with current antiretroviral therapies, is not presently curable due to infection with copies of the virus that is hidden and cannot be eliminated with existing medications.  However, investigators are now conducting studies to see if certain chemotherapy drugs may have a possible role in treating HIV infection itself, since these therapies effect cell DNA.  These therapies could potentially expose the hidden copies of the HIV virus which may then be attacked with effective antiretroviral therapy. The possible benefits and/or risks of this treatment, however, have not been adequately tested in humans, though several research studies are in progress or are being planned.

For a list of all the UCLA CARE Center's HIV and cancer studies conducted under the AIDS Malignancy Consortium (AMC), click here » 

The UCLA CARE Center is conducting one such study to test the safety of an experimental therapy, given at different dose levels in combination with a standard chemotherapy combination often administered to cancer patients, to find out what effects, good and/or bad, it has on the participants and their cancer:

AMC 078

Study examining the side effects and the best dose of vorinostat when given together with paclitaxel and carboplatin in treating patients with metastatic or recurrent solid tumors and HIV infection.  The researchers are particularly interested in aerodigestive tract tumors.

AMC 087

Phase I trial of Cabozantinib (XL 184) for advanced solid tumors in persons with HIV infection.

AMC 090

Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection

For more information about the UCLA CARE Center's clinical trials and research studies, please contact:
Phone:  (310) 557-9062
Email:  CAREOutreach@mednet.ucla.edu